Gadolinium-Based Contrast Agent Classification
Gadolinium-based contrast agents (GBCAs) are classified into three groups by the American College of Radiology based on their association with nephrogenic systemic fibrosis (NSF) risk 1.
Group I: High NSF Risk (No Longer Available in US)
These linear agents were linked to nearly all unconfounded NSF cases and have been withdrawn from the US market 1:
- Gadodiamide
- Gadoversetamide
- Gadopentetate dimeglumine
These agents had the lowest thermodynamic and kinetic stability, making them most susceptible to releasing free gadolinium through transmetallation 2.
Group II: Low NSF Risk
Few, if any, unconfounded cases of NSF have been associated with Group II agents 1. This group includes:
Linear ionic agent:
- Gadobenate dimeglumine (MultiHance)
Macrocyclic agents:
- Gadoterate meglumine (Dotarem, Clariscan)
- Gadobutrol (Gadavist)
- Gadoteridol (ProHance)
The macrocyclic structure provides superior stability compared to linear agents, with lower propensity for gadolinium dissociation 1, 2. Between 2017-2018, only a single unconfounded case of fibrosing dermopathy was reported with gadobenate dimeglumine in a patient with Stage 2 CKD 3.
Group III: Low NSF Risk
- Gadoxetate disodium (Eovist/Primovist) - approximately 5% hepatobiliary excretion 1
This agent also has minimal NSF association 3.
Structural Classification
GBCAs can alternatively be categorized by chemical structure 4, 5:
By chelate structure:
- Macrocyclic (cage-like structure): Higher stability, lower gadolinium deposition
- Linear (open-chain structure): Lower stability, higher gadolinium deposition
By charge:
- Ionic: Generally higher stability
- Nonionic: Lower stability
By biodistribution:
- Extracellular space agents: Most GBCAs
- Target/specific agents: Hepatobiliary agents (gadoxetate, gadobenate)
- Blood-pool agents: Specialized applications
The ACR Group II and III classification is the clinically relevant framework for NSF risk stratification and should guide agent selection in patients with kidney disease 1, 6.